Bridget Cleff

Bridget Cleff joined Decibel in April 2021 and brings over 20 years of expertise in strategy, new product planning, business development, marketing, and commercial operations in the life sciences industry. Bridget’s experience has focused on collaborating with R&D on pipeline programs and leading cross-functional strategies to bring innovative treatments to market to address patients’ unmet needs. She has a proven record of commercial pipeline planning from pre-clinical through launch across multiple therapeutic areas, including genetic diseases. Prior to Decibel, Bridget was Commercial Development Leader for the CNS gene therapy portfolio at Spark Therapeutics (acquired by Roche). Before Spark, Bridget was Vice President, New Products Commercial Strategy at Aevi Genomic Medicine, overseeing global commercial plans for the portfolio. Prior to Aevi, Bridget spent nine years at Takeda/Shire Pharmaceuticals, where she held roles of increasing responsibility, including commercial assessment for business development, marketing, and global market research.

In earlier roles, Bridget worked in strategic product development and operations management at Takeda Oncology/Millenium Pharmaceuticals, strategy consulting at The Wilkerson Group, and as a health economics researcher at the Leonard Davis Institute of Health Economics, University of Pennsylvania.

Bridget earned an MBA in entrepreneurial management and health care management from The Wharton School of the University of Pennsylvania and a BA in economics from Bucknell University.